×
About 3,103 results

ALLMedicine™ Estrogen Therapy Center

Research & Reviews  635 results

Management of postmenopausal women: Collège National des Gynécologues et Obstétriciens ...
https://doi.org/10.1016/j.maturitas.2022.05.008
Maturitas Trémollieres FA, Chabbert-Buffet N et. al.

Jun 20th, 2022 - The aim of these recommendations is to set forth an individualized approach to the management of early postmenopausal women (i.e., within the first 10 years after natural menopause) covering all aspects of lifestyle and therapeutic management, wit...

Urinary Free Cortisol
https://emedicine.medscape.com/article/2088848-overview

Jun 20th, 2022 - Reference Range Urinary free cortisol measurements are used primarily in the diagnosis of hypercortisolism caused by Cushing syndrome. [1, 2, 3] Reference ranges for urinary free cortisol vary by age, as follows: Age 0-2 years - Not established Ag...

Urinary Free Cortisol
https://emedicine.medscape.com/article/2088848-print

Jun 20th, 2022 - Urinary free cortisol measurements are used primarily in the diagnosis of hypercortisolism caused by Cushing syndrome.[1, 2, 3] Reference ranges for urinary free cortisol vary by age, as follows: Age 0-2 years - Not established Age 3-8 years - 1.4...

Long-term survival of non-localized epithelial ovarian cancer among women using menopau...
https://doi.org/10.1002/ijc.34171
International Journal of Cancer; Baandrup L, Galanakis M et. al.

Jun 19th, 2022 - Prediagnostic use of menopausal hormone therapy (MHT) has been suggested to be associated with improved survival of epithelial ovarian cancer (EOC). We investigated the potential long-term survival benefit of prediagnostic MHT use in women ≥50 yea...

Patient and Provider Web-Based Decision Support for Breast Cancer Chemoprevention: A Ra...
https://doi.org/10.1158/1940-6207.CAPR-22-0013
Cancer Prevention Research (Philadelphia, Pa.); Crew KD, Bhatkhande G et. al.

Jun 10th, 2022 - Significant under-utilization of breast cancer chemoprevention remains, despite guidelines stating that physicians should recommend chemoprevention with anti-estrogen therapy to high-risk women. We randomized women, age 35-75 years, who met high-r...

see more →

Guidelines  2 results

ACOG Committee Opinion No. 565: Hormone therapy and heart disease.
https://doi.org/10.1097/01.AOG.0000431053.33593.2d
Obstetrics and Gynecology;

Jul 3rd, 2013 - Menopausal hormone therapy should not be used for the primary or secondary prevention of coronary heart disease at the present time. Evidence is insufficient to conclude that long-term estrogen therapy or hormone therapy use improves cardiovascula...

The 2012 hormone therapy position statement of: The North American Menopause Society.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3443956
Menopause (New York, N.Y.);

Mar 1st, 2012 - This position statement aimed to update the evidence-based position statement published by The North American Menopause Society (NAMS) in 2010 regarding recommendations for hormone therapy (HT) for postmenopausal women. This updated position state...

see more →

Drugs  274 results see all →

Clinicaltrials.gov  93 results

Recurrent Urinary Tract Infections and Heparin (RUTIH Trial)
https://clinicaltrials.gov/ct2/show/NCT02246270

May 26th, 2022 - Primary Objectives: The specific aims of this study are to 1) demonstrate that Heparin bladder instillations reduce the number of UTI episodes; 2) demonstrate Heparin bladder instillations increase median intervals between UTI; and 3) demonstrate ...

Effects of a Tissue Selective Estrogen Complex (TSEC) on Depression and the Neural Reward System in the Perimenopause"
https://clinicaltrials.gov/ct2/show/NCT03740009

May 10th, 2022 - Despite decades of clinical research, depression continues to affect 20.9 million Americans each year and remains the leading cause of disability worldwide. Women are twice as likely as men to experience depression, and depression symptoms are par...

Sustainability of Vaginal Estrogen Therapy in Postmenopausal Women
https://clinicaltrials.gov/ct2/show/NCT02887885

Apr 27th, 2022 - Within this trial 50 postmenopausal women receive a vaginal estrogen therapy as treatment for symptomatic vaginal atrophy. The sustainability of vaginal estrogen therapy after the end of therapy has not yet been investigated. All participants will...

Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome
https://clinicaltrials.gov/ct2/show/NCT05221021

Apr 27th, 2022 - Background/significance: Overactive Bladder Syndrome (OAB) is defined as urinary urgency, with or without urgency incontinence, and usually accompanied by frequency and nocturia. OAB remains an increasingly more prevalent disease, affecting over 4...

Examining the Effects of Estradiol on Neural and Molecular Response to Reward
https://clinicaltrials.gov/ct2/show/NCT05282277

Apr 22nd, 2022 - The transition to menopause (the "perimenopause") is characterized by increased risk for new onset of depression and psychosis. Our work and that of others has demonstrated that a prominent symptom of perimenopausal-onset (PO) depression is anhedo...

see more →

News  229 results

Studies Explore a New Role for CDK4/6 Inhibition in HR+/HER2+ Breast Cancer and TNBC
https://www.onclive.com/view/studies-explore-a-new-role-for-cdk4-6-inhibition-in-hr-her2-breast-cancer-and-tnbc

Jan 3rd, 2022 - DATA FROM EARLY CLINICAL studies suggest a role for CDK4/6 inhibitor-based combinations in hormone receptor (HR)- positive, HER2-positive breast cancer and triple-negative breast cancer (TNBC). These data signify a new, nonchemotherapeutic alterna...

Premenopausal Bilateral Oophorectomy More Strongly Linked to Cognitive Decline
https://www.medpagetoday.com/endocrinology/menopause/95593

Nov 11th, 2021 - New research provides additional evidence that bilateral oophorectomy before menopause increases the risk of cognitive decline. In a retrospective case-control study of 2,732 women ages 50-89, bilateral oophorectomy before menopause and age 46 was...

ESMO Guidelines Recommend Personalized Treatment and Multidisciplinary Decision Making in Breast Cancer
https://www.onclive.com/view/esmo-guidelines-recommend-personalized-treatment-and-multidisciplinary-decision-making-in-breast-cancer

Nov 4th, 2021 - Irrespective of subtype, the management of metastatic breast cancer requires nuanced and multidisciplinary decision making to optimize and personalize locoregional, systemic, and supportive care, according to the ESMO Clinical Practice Guidelines ...

Menopause Society Issues First Osteoporosis Advice for 10 Years
https://www.medscape.com/viewarticle/958852

Sep 16th, 2021 - In the first revision to its guidance on the management of osteoporosis in a decade, The North American Menopause Society (NAMS) has issued an updated position statement addressing evolving evidence on osteoporosis issues ranging from screening an...

How to choose the right vaginal moisturizer or lubricant for your patient
https://www.mdedge.com/obgyn/article/241555/gynecology/how-choose-right-vaginal-moisturizer-or-lubricant-your-patient
Jon F. Pennycuff, MD, MSPH, Cheryl Iglesia, MD

Jun 15th, 2021 - Vaginal dryness, encompassed in the modern term genitourinary syndrome of menopause (GSM) affects up to 40% of menopausal women and up to 60% of postmenopausal breast cancer survivors. 1,2 Premenopausal women also can have vulvovaginal dryness whil.

see more →

Patient Education  8 results see all →